Table 2.
Comparison of clinical characteristics between the good control group and the poor control group.
| Good control group | Poor control group | p value | |
|---|---|---|---|
| (n = 16) | (n = 8) | ||
| Age, years | 51 [43–61] | 55 [52–67] | 0.26 |
| Sex, male | 5 (31.2) | 2 (25.0) | 1 |
| Diagnosis | |||
| DM | 6 (37.5) | 3 (37.5) | 0.66 |
| CADM | 10 (62.5) | 5 (62.5) | |
| Form of ILD | |||
| Acute | 2 (12.5) | 5 (62.5) | 0.06 |
| Subacute | 8 (50.0) | 2 (25.0) | |
| Chronic | 6 (37.5) | 1 (12.5) | |
| Smoking status, former | 6 (37.5) | 5 (62.5) | 0.44 |
| Pulmonary function indices (n = 22) | |||
| FVC, L | 2.3 [2.0–2.9] | 1.7 [1.5–2.1] | 0.07 |
| %FVC | 76.5 [68.2–82.3] | 71.6 [46.2–86.3] | 0.27 |
| FEV1, L | 1.7 [1.6–2.4] | 1.6 [1.5–1.7] | 0.15 |
| %FEV1 | 73.0 [58.8–85.4] | 59.8 [56.2–68.1] | 0.34 |
| Laboratory indices (at diagnosis) | |||
| WBC, /μL | 4900 [4185–5480] | 4600 [4125–7125] | 0.99 |
| CRP, mg/dL | 0.3 [0.2–1.6] | 1.1 [0.7–1.6] | 0.25 |
| CK, U/L | 55.5 [40.3–120.0] | 181.0 [87.5–275.8] | 0.20 |
| Aldolase, U/L | 8.1 [6.4–10.3] | 7.4 [5.9–10.8] | 0.83 |
| Ferritin, ng/mL | 407 [200–571] | 862 [400–980] | 0.14 |
| KL-6, U/mL | 742 [622–1031] | 838 [547–1166] | 0.95 |
| SP-D, ng/mL | 84.9 [40.7–108.6] | 36.2 [27.8–51.5] | 0.11 |
| IFN-λ3, pg/mL | 94.6 [21.1–120.8] | 129.0 [74.6–231.0] | 0.19 |
| Treatment | |||
| mPSL pulse therapy | 7 (43.8) | 6 (75.0) | 0.21 |
| CS + CNI | 14 (87.5) | 3 (28.6) | 0.02 |
| CS + CNI + cyclophosphamide | 2 (12.5) | 5 (71.4) | |
| Laboratory indices (at 1 month after treatment) | |||
| Ferritin, ng/mL | 344 [161–671] | 539 [293–1582] | 0.77 |
| KL-6, U/mL | 841 [680–946] | 1415 [1064–1575] | 0.09 |
| SP-D, ng/mL | 42.6 [29.9–88.3] | 123.6 [42.8–176.0] | 0.19 |
| IFN-λ3, pg/mL | 12.7 [6.3–22.0] | 118.8 [72.2–172.0] | 0.004 |
Data are presented as the median [interquartile range] or number (%).
CADM, Clinically amyopathic dermatomyositis; CK, Creatine kinase; CRP, C-reactive protein; CS, Corticosteroids; CNI, Calcineurin inhibitors; DM, Dermatomyositis; FEV1, Forced expiratory volume in 1 s; FVC, Forced vital capacity; IFN-λ3, Interferon-lambda 3; ILD, Interstitial lung disease; KL-6, Krebs von den Lungen-6; MDA5, Melanoma differentiation-associated gene 5; mPSL, Methylprednisolone; SP-D, Surfactant protein-D; WBC, White blood cell.